Detalhe da pesquisa
1.
An analysis of antibody responses and clinical sequalae of the Sinopharm HB02 COVID19 vaccine in dialysis patients in the United Arab Emirates.
Nephrology (Carlton)
; 27(3): 260-268, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-34569677
2.
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
JAMA
; 326(1): 35-45, 2021 07 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34037666
3.
Influence of COVID-19 pandemic on pregnancy and fertility preferences among the residents of the United Arab Emirates (UAE).
J Glob Health
; 14: 05002, 2024 Feb 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38330200
4.
Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
Vaccine
; 42(7): 1777-1784, 2024 Mar 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38365482
5.
Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.
Vaccines (Basel)
; 11(2)2023 Jan 30.
Artigo
Inglês
| MEDLINE | ID: mdl-36851177
6.
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.
Signal Transduct Target Ther
; 8(1): 20, 2023 01 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36596779
7.
The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
Sci Rep
; 12(1): 490, 2022 01 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35017530
8.
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Signal Transduct Target Ther
; 7(1): 172, 2022 06 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35665745
9.
Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates.
Nat Commun
; 13(1): 3215, 2022 06 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35680857
10.
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
Nat Commun
; 13(1): 3654, 2022 06 27.
Artigo
Inglês
| MEDLINE | ID: mdl-35760812